HC Wainwright Reaffirms “Buy” Rating for XOMA (NASDAQ:XOMA)

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $104.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 393.83% from the company’s current price.

Separately, StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th.

XOMA Trading Up 0.8 %

NASDAQ XOMA opened at $21.06 on Wednesday. The stock has a market capitalization of $248.15 million, a price-to-earnings ratio of -6.05 and a beta of 1.00. XOMA has a 52 week low of $19.92 and a 52 week high of $35.00. The stock’s 50 day moving average price is $24.45 and its two-hundred day moving average price is $27.20. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, analysts anticipate that XOMA will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.20% of the stock is owned by insiders.

Institutional Trading of XOMA

Several institutional investors have recently added to or reduced their stakes in the company. Nuveen Asset Management LLC boosted its stake in XOMA by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 527 shares during the period. BNP Paribas Financial Markets boosted its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund boosted its stake in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 800 shares during the period. Eversept Partners LP boosted its stake in XOMA by 1.2% in the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after purchasing an additional 1,128 shares during the period. Finally, Geode Capital Management LLC boosted its stake in XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the period. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.